Femasys Inc.

Femasys Inc. is a biomedical company with a mission to revamp women’s healthcare globally. The company is dedicated to developing groundbreaking solutions and next-generation advancements to tackle areas that are currently underrepresented in the healthcare landscape. Femasys initially focuses on reproductive health, offering two lead product candidates: FemBloc®, the first and only non-surgical product for permanent birth control, and FemaSeed™, a directed sperm delivery product for infertility treatment. Moreover, Femasys’ FemVue® for fallopian tube assessment by ultrasound is its primary commercial priority in the United States. The company has also engineered a pioneering technology platform for tissue sampling, intended for marketing alongside its other women-specific medical products in the physician’s office setting. Established in 2004 and headquartered in the United States, Femasys recently garnered a $6.85M Post-IPO Debt investment on 15 November 2023 from PharmaCyte Biotech. Femasys is at the vanguard of medical innovation, addressing pressing needs in women’s healthcare with its groundbreaking products and technologies.